Jason van Ittersum, MD
Dermatology · Norton Shores, MINPI 1750303079
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.1% of the total across 55 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 19 manufacturers reported payments, led by Merz North America, Inc. at 32.8% of the total. Reporting peaked in 2019 at $1,243 and has fallen 91.7% since, to $103 in 2025. That places this record below the midpoint for dermatology clinicians in MI, where the typical reported total is $2,933.
Across 55 payments — averaging $27.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merz North America, Inc.$490
- AbbVie$301
- Regeneron Healthcare Solutions, Inc.$209
- Mayne Pharma Commercial LLC$93
- Prugen, Inc. Pharmaceuticals$58
- Lilly USA, LLC$52
- plus $290 from 13 others
Across 28 payments — averaging $1567.35 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$44K
What the payments were for
- Food & beverage$1,42095%
- Education$735%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merz North America, Inc. | 2 | $490 |
| AbbVie(2 entities) | 14 | $301 |
| Regeneron Healthcare Solutions, Inc. | 8 | $209 |
| Mayne Pharma Commercial LLC | 6 | $93 |
| Prugen, Inc. Pharmaceuticals | 4 | $58 |
| Lilly USA, LLC | 4 | $52 |
| Pfizer | 3 | $43 |
| Bristol Myers Squibb | 1 | $33 |
| Amgen | 2 | $33 |
| LEO Pharma Inc. | 2 | $30 |
| Boehringer Ingelheim | 1 | $25 |
| Promius Pharma LLC | 1 | $18 |
| Novartis | 1 | $18 |
| Genentech USA, Inc. | 1 | $17 |
| Almirall LLC | 1 | $16 |
| Dermira, Inc. | 1 | $16 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 1 | $15 |
| Dentsply Sirona Inc | 1 | $14 |
| Galderma Laboratories, L.p. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XEOMIN$490
How this compares
$1,493 in reported general payments places this provider in the 35th percentile of 404 dermatology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OtezlaApremilast | 28 | $119,373 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 11 | $76,096 |
| Dupixent PenDupilumab | 14 | $54,382 |
| Dupixent SyringeDupilumab | 14 | $48,161 |
| Betamethasone Dipropionate | 449 | $17,995 |
| Calcipotriene | 95 | $15,710 |
| Fluorouracil | 243 | $14,980 |
| Clobetasol Propionate | 443 | $12,937 |
| Metronidazole | 98 | $7,527 |
| Pimecrolimus | 27 | $5,840 |
| Tacrolimus | 44 | $4,456 |
| Ketoconazole | 201 | $4,060 |
| Tretinoin | 41 | $3,637 |
| Triamcinolone Acetonide | 489 | $3,458 |
| Doxycycline Hyclate | 138 | $2,964 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenOtezla | $33 | $119,37328 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 404 dermatology providers in Michigan.
Other dermatology in Norton Shores
- Linda Stein GoldWest Bloomfield$3.3M
- Kristi HawleyCaledonia$2.2M
- David AltmanWarren$1.9M
- Michael SiegelWaterford$708K
- Johann GudjonssonAnn Arbor$535K
- Michael DormanWest Bloomfield$433K
- Steven DaveluyDearborn$350K
- Benjamin WorkmanMidland$284K
- Diana WestgateKalamazoo$252K
- Christofer BuattiAuburn Hills$247K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.